Navigation Links
MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources

MOUNTAIN VIEW, Calif., May 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Marco F. Rosa to the newly created position of Vice President of Human Resources.

Mr. Rosa brings over 20 years of human resources experience to the Company. Most recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. as Vice President of Worldwide Human Resources, a position he had held since May of 2002. He was an integral part of the senior management team overseeing the company's growth and the commercial launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at COR Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. Before joining COR, Mr. Rosa held senior human resources and key administrative management positions with ReplayTV, Inc., Genelabs Technologies, Inc., and Sony Electronics Inc. Prior to 1990, Mr. Rosa held similar management positions with the General Electric Company where he started his career in human resources.

"I'm pleased to have Marco join our management team and help to develop the future of the company as we continue our late-stage product development and move toward potential commercialization," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "Marco brings unique company building expertise to our efforts to develop improved therapies for children and adults who suffer from diseases that we believe are not adequately treated by currently available medicines."

In addition to his extensive human resources experience, Mr. Rosa served as a Captain in the BioMedical Corps of the United States Air Force. Mr. Rosa received his B.A. degree in Psychology from St. Michael's College and his M.A. degree in Counseling Psychology from New York University.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
2. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
5. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
6. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
7. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
8. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
9. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
10. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
11. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
(Date:10/27/2015)... Calif. , Oct. 27, 2015 Synaptics Inc. ... solutions, today announced that Google has adopted the Synaptics ... touch controller solutions to power its newest flagship smartphones, ... by Huawei. --> ... like Google to provide strategic collaboration in the joint ...
(Date:10/23/2015)... and GOLETA, California , October 23, ... BIOPAC and SensoMotoric Instruments (SMI) announce a mobile plug ... data captured during interactive real-world tasks SensoMotoric ... integration of their established wearable solutions for eye tracking ... gaze behavior captured with SMI Eye Tracking Glasses ...
Breaking Biology News(10 mins):